Clinical Trials
62 trialsA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
NAUTIKA1
Genentech, Inc.
TAPUR
American Society of Clinical Oncology
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
DARWINII
University College, London
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Scripps Health
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
CAPTUR
Canadian Cancer Trials Group
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
CUPISCO
Hoffmann-La Roche
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
AcSé
UNICANCER
ProTarget
Rigshospitalet, Denmark
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
ImmunoCobiVem
University Hospital, Essen
NEO-TIM
Fondazione Melanoma Onlus
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Alliance for Clinical Trials in Oncology
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
SPRING
Peking University Shenzhen Hospital
Irinotecan Hydrochloride Liposome Injection (â…¡) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Shanghai Changzheng Hospital
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
FINPROVE
Helsinki University Central Hospital
MODUL
Hoffmann-La Roche
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
IMPRESS-N
Oslo University Hospital
DRUP
The Netherlands Cancer Institute
ROME
Fondazione per la Medicina Personalizzata
RadioCoBRIM
Technische Universität Dresden
mCRC
Shanghai Kechow Pharma, Inc.
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
VECODUE
Fondazione Melanoma Onlus
NEO-VC
University Hospital Tuebingen
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
SWOG Cancer Research Network
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
COWBOY
Radboud University Medical Center
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Grupo Español Multidisciplinar de Melanoma
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
MetAction
Oslo University Hospital